These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11750331)

  • 1. Optimization of cyclosporine exposure utilizing C(2) level monitoring in de novo renal transplant recipients: the Toronto General Hospital experience.
    Maham N; Cardella C; Cattran D; Fenton S; O'Grady C; Hamill J; Smith R; Cole E
    Transplant Proc; 2001; 33(7-8):3098-9. PubMed ID: 11750331
    [No Abstract]   [Full Text] [Related]  

  • 2. C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients.
    Citterio F; Scatà MC; Borzi MT; Pozzetto U; Castagneto M
    Transplant Proc; 2001; 33(7-8):3133-6. PubMed ID: 11750347
    [No Abstract]   [Full Text] [Related]  

  • 3. Three-hour postdose cyclosporine level monitoring: less rejection and more nephrotoxicity?
    Domínguez J; Tomic A; Norambuena R
    Transplant Proc; 2001; 33(7-8):3120-1. PubMed ID: 11750341
    [No Abstract]   [Full Text] [Related]  

  • 4. Conventional versus Neoral cyclosporine in renal transplantation.
    Rovelli E; Bucci A; Maldifassi P; Belfiore A; D'Amico G
    Transplant Proc; 1998 Aug; 30(5):1764-5. PubMed ID: 9723272
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclosporine A: peak or trough level monitoring in renal transplant recipients?
    Wacke R; Drewelow B; Kundt G; Hehl EM; Bast R; Seiter H
    Transplant Proc; 2001; 33(7-8):3122-3. PubMed ID: 11750342
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyclosporine Neoral profiling in Japanese renal transplant recipients.
    Aikawa A; Arai K; Tajima E; Kawamura T; Ogiwara H; Sakai K; Mizuiri S; Ohara T; Hasegawa A; Kosugi T; Kusano A; Matsuo K; Obayashi M; Kurokawa M
    Transplant Proc; 2001; 33(7-8):3142-5. PubMed ID: 11750350
    [No Abstract]   [Full Text] [Related]  

  • 7. Feasibility of changing therapeutic cyclosporine monitoring from C(0) to C(2) in stable renal recipients: narrower coefficient of variation with C(2) monitoring.
    Chueh SC; Liao CH; Chang CJ; Lai MK
    Transplant Proc; 2001; 33(7-8):3100-1. PubMed ID: 11750332
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of trough level and C(2) cyclosporine blood concentration monitoring in outpatient kidney transplant recipients.
    Braun F; Armstrong VW; Lorf T; Canelo R; Arndt C; Oellerich M; Ringe B
    Transplant Proc; 2001; 33(7-8):3108-9. PubMed ID: 11750336
    [No Abstract]   [Full Text] [Related]  

  • 9. C0/C2 cyclosporine levels monitoring in renal transplantation.
    Santana A; Guerra J; Milhomens C; Neves F; Prata MM
    Transplant Proc; 2003 May; 35(3):1072-3. PubMed ID: 12947862
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoral (cyclosporine) C2 monitoring in renal transplant recipients: a single-center experience in Asia.
    Wong HS; Morad Z
    Transplant Proc; 2003 Feb; 35(1):230-1. PubMed ID: 12591376
    [No Abstract]   [Full Text] [Related]  

  • 11. Single-center study utilizing C(2) level as monitoring tool in de novo renal transplant recipients treated with Neoral.
    Keshavamurthy M; Al Ahmadi I; Mohammed Raza S; Baynton R; Al Meshari K; Al Shaibani K
    Transplant Proc; 2001; 33(7-8):3112-4. PubMed ID: 11750338
    [No Abstract]   [Full Text] [Related]  

  • 12. Can three-times-a-day cyclosporine Neoral avoid cyclosporine toxicity in renal transplant recipients? A pharmacokinetic study.
    Swart N; Botha J; Tandon V; Michaels P; Pontin AR; Halkett J; Pascoe MD; Kahn D
    Transplant Proc; 2001; 33(7-8):3140-1. PubMed ID: 11750349
    [No Abstract]   [Full Text] [Related]  

  • 13. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome.
    Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R
    Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243
    [No Abstract]   [Full Text] [Related]  

  • 14. Conversion from Sandimmune to Neoral in renal transplant recipients: two-year experience.
    Wilczek HE; Akesson P; Warholm C
    Transplant Proc; 1998 Aug; 30(5):1753-5. PubMed ID: 9723267
    [No Abstract]   [Full Text] [Related]  

  • 15. A retrospective analysis of Neoral C2 monitoring in Chinese renal transplantation recipients.
    Tan J; Tang X
    Transplant Proc; 2003 Feb; 35(1):232-3. PubMed ID: 12591377
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and effectiveness of microemulsion cyclosporine in renal allograft recipients: 1-year follow-up study.
    Park K; Kim MS; Kim SI; Kim YS; Moon JI
    Transplant Proc; 1998 Nov; 30(7):3556-7. PubMed ID: 9838557
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation.
    Yu L; Wang Y; Fu SJ; Cheng XJ
    Transplant Proc; 2000 Nov; 32(7):1709-10. PubMed ID: 11119902
    [No Abstract]   [Full Text] [Related]  

  • 18. Conversion of C-0 to C-2 monitoring of cyclosporine in stable kidney transplant patients.
    Jirasiritham S; Mavichak V; Danviriyasup K; Jirasiritham S
    Transplant Proc; 2003 Feb; 35(1):236-7. PubMed ID: 12591379
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimization of cyclosporine therapy with abbreviated area under the curve method in renal transplant.
    Yang WC; Chen YF; King KL; Wu TH; Chen Hsu RY ; Tang JJ; Loong CC; Chou MH; Lin MF; Lui WY
    Transplant Proc; 2000 Nov; 32(7):1685-7. PubMed ID: 11119892
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring.
    Sharma A; Shekhar C; Heer M; Minz M
    Transplant Proc; 2006 Sep; 38(7):2051-3. PubMed ID: 16979996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.